Remodeling the Extracellular Matrix to Overcome Immune Exclusion

22 concepts12 papers1 proposal

Immunotherapy has fundamentally changed oncology, but its success remains largely confined to liquid tumors and highly inflamed "hot" malignancies. For many solid tumors, the primary obstacle is not just a lack of immune recognition, but a physical fortress. The tumor microenvironment builds a dense, rigid structural barrier known as the desmoplastic stroma. Composed of heavily cross-linked collagen networks, hyaluronic acid (HA), and proteoglycans, this extracellular matrix (ECM) creates a high-pressure physical wall that excludes therapeutic agents, T cells, and natural killer (NK) cells from the tumor core.

As highlighted by Chen Wang et al. and Rui Zheng et al. in the context of pancreatic cancer, this dense stromal fortress actively drives an "immune-excluded" phenotype. To breach these defenses, a rapidly growing research direction focuses on physically remodeling the tumor matrix. Rather than relying solely on immune-centric checkpoint inhibitors, researchers are developing bioengineering strategies to dismantle this physical architecture, transforming impenetrable "cold" tumors into accessible, "immune-inflamed" environments.


Active Digestion: Arming Therapeutics with Molecular Scissors

The most direct way to breach a wall is to chew through it. One major facet of this research direction involves engineering therapeutic delivery systems and adoptive cells to autonomously secrete matrix-degrading enzymes. By localizing enzymatic activity directly within the tumor, these platforms clear physical obstructions without causing systemic toxicity.

[Engineered Immune Cell] ──> Secretes Enzymes (Heparanase / Hyaluronidase)
                                    │
                                    ▼
                     [Degrades Dense ECM Components]
                                    │
                                    ▼
             [Lowers Matrix Density & Opens Physical Channels]
                                    │
                                    ▼
            [Infiltration of Cytotoxic T/NK Cells into Core]

Cellular Siege Engines

In adoptive cell therapies like CAR-T and CAR-NK, cells frequently stall at the tumor periphery. To overcome this, Binglan Zhang et al. and Mengke Niu et al. describe the utility of engineering these therapeutic cells to express stroma-degrading enzymes such as heparanase. This modification allows the cells to autonomously degrade the dense carbohydrate chains of the ECM, facilitating deeper penetration and sustained anti-tumor activity.

Similarly, Ruocong Zhao et al. demonstrated that engineering CAR-T cells to co-express a secreted form of human hyaluronidase (sPH20-IgG2) successfully breaks down hyaluronic acid (HA) in gastric cancers. Crucially, the authors noted that this enzymatic activity did not compromise the cells' intrinsic cytotoxicity or cytokine profiles; instead, it selectively cleared the physical path, leading to superior tumor regression and lymphocyte infiltration in preclinical models.

Vector and Nanocarrier Delivery

Beyond living cells, other therapeutic modalities are being "armed" with similar matrix-clearing capabilities:

  • Oncolytic Viruses: Xue Li et al. engineered an oncolytic adenovirus to express the proteoglycan Decorin (DCN). The delivery of DCN degraded the tumor stroma and downregulated downstream immunosuppressive signals like TGF-β and VEGF, turning a hostile environment into a permissive site for adoptive NK cell therapy.
  • Smart Nanoparticles: Min Zhang et al. reviewed how integrating hyaluronidase into advanced delivery systems (such as those used in photodynamic therapy) breaks down the physical matrix. This degradation reverses local hypoxia and allows mature dendritic cells and cytotoxic T cells to migrate from the tumor periphery into the core.

Architectural Disruption: Halting Matrix Synthesis and Cross-Linking

While active digestion cuts through existing barriers, an alternative and complementary strategy aims to stop the construction and stiffening of the wall altogether. This is achieved by targeting the signaling pathways responsible for matrix deposition and mechanical cross-linking.

Softening the Matrix via Lysyl Oxidase Inhibition

The mechanical stiffness of the ECM is a dynamic property. As Zizhao Mai et al. explained, matrix rigidity is driven by the cross-linking of collagen fibers, a process heavily mediated by enzymes like lysyl oxidase. By utilizing lysyl oxidase inhibitors or hyaluronidase, researchers can reduce the physical density and rigidity of the tumor microenvironment. Softening the matrix lowers the mechanical resistance that immune cells encounter, drastically boosting the efficacy of standard immunotherapies.

Neutralizing the Master Builder: TGF-β Blockade

The primary orchestrator of this stromal construction is Transforming Growth Factor-beta (TGF-β). TGF-β drives the transition of resting fibroblasts into activated, matrix-secreting cancer-associated fibroblasts (CAFs).

TGF-β Signaling ──> Activates Fibroblasts (CAFs) ──> High Collagen Deposition & Cross-linking ──> Rigid Physical Barrier (Immune Exclusion)
                                                                                                        │
[Dual Blockade (Anti-PD-1/L1 + Anti-TGF-β)] ────────────────────────────────────────────────────────────┘
         │
         ▼
Inhibits CAF Activation ──> Reduced Collagen Density ──> Softened Microenvironment ──> T-Cell Infiltration (Immune Inflamed)

To disrupt this process, researchers are developing bifunctional therapies that simultaneously block immune checkpoints and neutralize TGF-β:

  • Bispecific Antibodies: Xinrun Wang et al. and Mengke Niu et al. detailed a new generation of bispecific antibodies targeting both the PD-1/PD-L1 axis and TGF-β. By neutralizing TGF-β, these molecules reduce peritumoral collagen density and reverse the epithelial-mesenchymal transition (EMT). As a result, the physical architecture is dismantled, converting immune-excluded phenotypes into inflamed ones.
  • Overcoming Specific Resistances: In HPV-associated cancers, Mengke Niu et al. demonstrated that this dual blockade suppresses CAF activation, directly reducing the dense collagen networks that trap cytotoxic T cells at the periphery.
  • Enzyme-Responsive Delivery: Taking localization a step further, Ying‐Tzu Yen et al. developed gelatinase-responsive nanoparticles that release anti-PD-1 and TGF-β inhibitors exclusively inside the tumor. This localized inhibition prevents the fibroblast-to-myofibroblast transition, significantly reducing collagen deposition and softening the tumor microenvironment to unlock robust therapeutic efficacy.

Why This Strategy Works: From Exclusion to Infiltration

The shift toward physical microenvironment remodeling works because it addresses a fundamental law of cellular migration: immune cells cannot kill cancer cells they cannot reach.

In a classic "cold" or "immune-excluded" tumor, T cells may be fully activated and tumor-specific, but they remain trapped in the peritumoral stroma, physically blocked by dense collagen ropes and high interstitial fluid pressures caused by hyaluronic acid accumulation.

By combining immune checkpoint inhibitors with matrix-degrading enzymes (like heparanase or hyaluronidase) or matrix-softening agents (like TGF-β inhibitors), the structural integrity of the stroma is compromised. This mechanical intervention opens physical channels within the ECM, lowers interstitial pressure, and reduces tissue rigidity. Consequently, the physical barriers are lowered, allowing cytotoxic lymphocytes to freely infiltrate the tumor core and execute their cytolytic programs. Remodeling the physical architecture of the tumor microenvironment is proving to be the key that unlocks the full potential of cancer immunotherapy.

Key Foundational Work

Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer (2021) — contributed 4 concept elements to this direction.
Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors (2016) — contributed 2 concept elements to this direction.
History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 12 papers
  2. Version 1 · 2026-10-04 · 12 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_tumor_microenvironment_remodeling_453cd9f0,
  title = {tumor microenvironment remodeling},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/tumor-microenvironment-remodeling/rdr_453cd9f0c114479ca788f36d6e5cd34f},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-21},
}

This exact version (version 2, frozen text):

@misc{lacuna_tumor_microenvironment_remodeling_453cd9f0_v2,
  title = {tumor microenvironment remodeling},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/tumor-microenvironment-remodeling/rdr_453cd9f0c114479ca788f36d6e5cd34f/v/2},
  note = {Version 2, frozen 2026-10-04. Accessed 2026-11-21},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake